Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing

Executive Summary

Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.

You may also be interested in...



Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU

Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel